Dalpiciclib

Dalpiciclib is a drug for the treatment of various forms of cancer.[1] In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.[2] Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.This antineoplastic or immunomodulatory drug article is a stub.You can help Wikipedia by expanding it.
IUPAC nameCAS NumberIUPHAR/BPSDrugBankChemSpiderChEMBLFormulaMolar massSMILESfulvestrantHR-positiveHER2-negativemetastatic breast cancerCDK inhibitorantineoplasticimmunomodulatory